Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 182,132	$ 54,004
Available-for-sale securities	90,763	251,212
Accounts receivable	3,975	933
Related party accounts receivable, net	56,382	63,921
Inventory		1,081
Prepaid expenses and other current assets	8,235	9,030
Total current assets	341,487	380,181
Restricted cash	7,057	8,247
Property and equipment, net	17,854	20,512
Convertible note hedges	171,880	132,521
Intangible assets, net	165,278	166,119
Goodwill	785	785
Other assets	738	1,456
Total assets	705,079	709,821
Current liabilities:
Accounts payable and related party accounts payable, net	21,190	17,703
Accrued research and development costs	7,454	6,937
Accrued expenses and other current liabilities	30,817	38,301
Current portion of capital lease obligations	5,097	6,227
Current portion of deferred rent	205	7,719
Deferred revenue	225
Current portion of contingent consideration	14,985	14,244
Total current liabilities	79,973	91,131
Capital lease obligations, net of current portion		82
Deferred rent, net of current portion	3,515	557
Contingent consideration, net of current portion	71,213	63,416
Note hedge warrants	149,458	113,237
Other liabilities	8,190	8,190
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding
Additional paid-in capital	1,293,292	1,258,398
Accumulated deficit	(1,288,548)	(1,191,823)
Accumulated other comprehensive loss	(24)	(7)
Total stockholders’ equity	4,870	66,716
Total liabilities and stockholders’ equity	705,079	709,821
Class A common stock
Stockholders’ equity:
Common stock	135	133
Class B common stock
Stockholders’ equity:
Common stock	15	15
2.25% Convertible Senior Notes due in 2022
Current liabilities:
Notes payable	241,544	234,243
11% PhaRMA Notes
Current liabilities:
Notes payable		$ 132,249
8.375% Notes due 2026
Current liabilities:
Notes payable	$ 146,316